Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

First Opinion Lung-I Cheng

Five years after Kymriah: Ensuring the next cell and gene therapies reach patients

Kymriah, the first cell and gene therapy, was approved five years ago. It will take work to get the next wave of these therapies to patients.

Read The Story

Pharmalot Allison DeAngelis

Pharmalittle: The ‘godfather’ of biotech trying to save Biogen; pharma companies grapple with ADHD drug shortages

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Centene agrees to pay $33 million to resolve another state probe into its pharmacy benefits business

Pharmalot Ed Silverman

Major Indian generic drugmaker closes a U.S. facility after years of manufacturing problems

All Coverage

Pharmalot Ed Silverman

Pharmalittle: Moderna sues Pfizer over Covid-19 vax patents; White House directs quick access to federally funded research

Pharmalot Ed Silverman

Pharmalittle: House report shows Trump sought to pressure FDA on Covid response; Pfizer Covid pill provides little benefit to younger adults

Pharma Matthew Herper

Pfizer’s experimental RSV vaccine protects older adults in study

Pharmalot Ed Silverman

Pharmalittle: AstraZeneca may exit the vaccine business; Bavarian Nordic looks at expired monkeypox vax doses to boost supplies

Pharmalot Ed Silverman

Pharmalittle: Biden plan to stretch monkeypox vax supplies hits problems; Pfizer and BioNTech ask FDA to clear Covid shot for variants

Pharmalot Ed Silverman

Pharmalittle: Murky online market for abortion pills is thriving; more ‘cash pay’ pharmacies decline insurance in the U.S.

Pharmalot Ed Silverman

FDA scolds Sun Pharma for allegedly backdating documents and fudging records for collecting drug samples

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: Biden plan to shift cost of Covid-19 products to consumers; U.S. company to help with monkeypox shot production

Pharmalot Ed Silverman

Medicare may eventually negotiate some drug prices, but Colorado still wants to import medicines from Canada

Pharmalot Ed Silverman

Pharmalittle: FDA approves a gene therapy for a rare blood disorder; pharmacy chains ordered to pay $650 million over opioid crisis

Pharmalot Ed Silverman

‘A blind eye’: NIH fails to ensure clinical trial results are reported, and still funds researchers who don’t file results

Pharmalot Ed Silverman

Pharmalittle: Endo files for bankruptcy protection due to opioid suits; first Zantac lawsuit dropped, giving GSK a boost

Pharmalot Ed Silverman

Cepheid faces fresh criticism over the pricing of its TB diagnostics

Pharmalot Ed Silverman

Pharmalittle: Activist investor targets Cardinal Health; 340B drug sales rose to $44 billion last year

Biotech Jason Mast

Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup

Pharmalot Ed Silverman

Sales from controversial drug discount program rose to $44 billion last year

Pharmalot Ed Silverman

Pharmalittle: U.S. House passes drug-pricing legislation; U.K. is first country to approve a bivalent Covid shot

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: Two children died after getting Novartis gene therapy; monkeypox vaccine maker warns about splitting doses

Pharmalot Ed Silverman

Wyden wants details on Amgen’s U.S. taxes as part of expanding probe into pharma practices

Exclusive Ed Silverman

Novartis reports two children died from acute liver failure after treatment with Zolgensma gene therapy

The Pharmalot View Ed Silverman

‘Window dressing’: Eli Lilly’s after-the-fact statement on Indiana’s abortion law sends a disingenuous message

Pharmalot Ed Silverman

Pharma

Five years after Kymriah: Ensuring the next cell and gene therapies reach patients

Pharmalittle: The ‘godfather’ of biotech trying to save Biogen; pharma companies grapple with ADHD drug shortages

Up and down the ladder: The latest comings and goings

Centene agrees to pay $33 million to resolve another state probe into its pharmacy benefits business

Major Indian generic drugmaker closes a U.S. facility after years of manufacturing problems

All Coverage

Pharmalittle: Moderna sues Pfizer over Covid-19 vax patents; White House directs quick access to federally funded research

Pharmalittle: House report shows Trump sought to pressure FDA on Covid response; Pfizer Covid pill provides little benefit to younger adults

Pfizer’s experimental RSV vaccine protects older adults in study

Pharmalittle: AstraZeneca may exit the vaccine business; Bavarian Nordic looks at expired monkeypox vax doses to boost supplies

Pharmalittle: Biden plan to stretch monkeypox vax supplies hits problems; Pfizer and BioNTech ask FDA to clear Covid shot for variants

Pharmalittle: Murky online market for abortion pills is thriving; more ‘cash pay’ pharmacies decline insurance in the U.S.

FDA scolds Sun Pharma for allegedly backdating documents and fudging records for collecting drug samples

Up and down the ladder: The latest comings and goings

Pharmalittle: Biden plan to shift cost of Covid-19 products to consumers; U.S. company to help with monkeypox shot production

Medicare may eventually negotiate some drug prices, but Colorado still wants to import medicines from Canada

Pharmalittle: FDA approves a gene therapy for a rare blood disorder; pharmacy chains ordered to pay $650 million over opioid crisis

‘A blind eye’: NIH fails to ensure clinical trial results are reported, and still funds researchers who don’t file results

Pharmalittle: Endo files for bankruptcy protection due to opioid suits; first Zantac lawsuit dropped, giving GSK a boost

Cepheid faces fresh criticism over the pricing of its TB diagnostics

Pharmalittle: Activist investor targets Cardinal Health; 340B drug sales rose to $44 billion last year

Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup

Sales from controversial drug discount program rose to $44 billion last year

Pharmalittle: U.S. House passes drug-pricing legislation; U.K. is first country to approve a bivalent Covid shot

Up and down the ladder: The latest comings and goings

Pharmalittle: Two children died after getting Novartis gene therapy; monkeypox vaccine maker warns about splitting doses

Wyden wants details on Amgen’s U.S. taxes as part of expanding probe into pharma practices

Novartis reports two children died from acute liver failure after treatment with Zolgensma gene therapy

‘Window dressing’: Eli Lilly’s after-the-fact statement on Indiana’s abortion law sends a disingenuous message

Pharmalittle: Judge rules Walgreens helped fuel San Francisco opioid crisis; U.S. plan to bottle monkeypox vaccine could take months

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day